Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211484 · ClinicalTrials.gov registry record · Phase 2
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00211484 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 5 participants.
The verdict
NCT00211484, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a fine point laser beam) have not been found to be effective in treating the lesions these patients have. Anecortave acetate is an experimental drug that is being tested to prevent the growth of blood vessels under the retina in patients with age-related macular degeneration (AMD).
Interventions
- DRUG Anecortave Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211484
The ClinicalTrials.gov registry entry for NCT00211484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate is the first listed.
NCT00211484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211484 about?
NCT00211484 is a clinical study titled "Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.". A compassionate method of treatment is offered to patients where lesions do not meet acceptable criteria for standard therapy. Visudyne (Photodynamic Therapy) and laser photocoagulation treatment (a treatment using heat from a fine point laser beam) have not been found to be effective in treating th...
What is the current status of trial NCT00211484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2003-05. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00211484?
The interventions under investigation include: Anecortave Acetate (DRUG).
Who is sponsoring clinical trial NCT00211484?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.